COGT - NASDAQ

Cogent Biosciences, Inc.

COGT·NASDAQ

$32.26

+0.19%

HealthcareBiotechnology

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$5.51B

EPS-2.5500

P/E Ratio-12.65

Earnings Date08/04/2026

937.61M

Assets

186%

3Y+212.0%

5Y+274.0%

10Y+1141.0%

301.24M

Total Liabilities

321%

3Y+568.0%

5Y+1754.0%

10Y+1201.0%

636.37M

Total Equity

148%

3Y+149.0%

5Y+171.0%

10Y+1115.0%

Cogent Biosciences, Inc. Funding & Solvency Profile

COGT · NASDAQ

Current Assets

Cash & Cash Equivalents312.01M

Net Receivables0.00

Inventory0.00

Other Current Assets9.59M

Total Current Assets910 M

Non-Current Assets

Property, Plant & Equipment23.54M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets3.72M

Total Non-Current Assets27 M

Total Assets

937.61M

Financial Health Analysis

Current Ratio

14.23x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.47x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

846 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cogent Biosciences, Inc. Balance Sheet

COGT • NASDAQ

Cogent Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	312M	98.2M	53.2M	139.9M	219.7M	242.2M	37.4M	55.7M	28.3M	41.3M	90.5M
Short-Term Investments	588.8M	188.9M	212.5M	119.4M	0.0	0.0	0.0	22.9M	12.7M	27.2M	0.0
Cash & Short-Term Investments	900.8M	287.1M	265.7M	259.3M	219.7M	242.2M	37.4M	78.6M	41M	68.5M	90.5M
Net Receivables	0.0	0.0	0.0	0.0	0.0	0.0	2M	1.7M	830K	928K	294K
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	2M	1.7M	830K	928K	294K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	75K	0.0	0.0
Prepaids	0.0	0.0	0.0	4.4M	2.9M	2.7M	1.2M	740K	513K	296K	0.0
Other Current Assets	9.6M	9.4M	5.1M	1.3M	0.0	0.0	0.0	740K	75K	0.0	326K
Total Current Assets	910.4M	296.5M	270.8M	265M	222.6M	244.9M	40.6M	81M	42.4M	69.7M	91.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	23.5M	26.6M	30.3M	31.1M	4.5M	4.7M	7.2M	3.3M	4.1M	4.6M	2.4M
Long-Term Investments	0.0	0.0	7.5M	0.0	0.0	0.0	0.0	1.3M	1.3M	1.3M	1.3M
Other Non-Current Assets	3.7M	4.9M	4.9M	4.7M	5M	1.3M	1.7M	419K	1.4M	0.0	0.0
Total Non-Current Assets	27.3M	31.4M	42.7M	35.8M	9.5M	6M	8.8M	4.9M	6.7M	5.8M	3.7M
Total Assets	937.6M	327.9M	313.4M	300.8M	232.1M	250.9M	49.4M	85.9M	49.1M	75.6M	94.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.5M	12M	10.7M	5.8M	3.5M	732K	3.2M	1.5M	1.3M	1.5M	1.4M
Accounts Payable	9.5M	12M	10.7M	5.8M	3.5M	732K	3.2M	1.5M	1.3M	1.5M	1.4M
Accrued Expenses	0.0	29.5M	15.8M	11.4M	4.6M	3M	3.7M	1.6M	1.3M	1.2M	0.0
Short Term Debt	1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.6M	1.4M	1.4M	2.3M	2.1M	1.6M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	1.7M	3.1M	0.0	1.3M	17.9M	6.9M	6M	5.3M
Other Current Liabilities	52.9M	12.6M	10.3M	6.5M	3.6M	7.3M	3.4M	3.9M	1.6M	118K	606K
Total Current Liabilities	64M	55.7M	38.2M	26.8M	17.1M	13.1M	13.2M	24.9M	11.2M	8.7M	7.3M
NON-CURRENT LIABILITIES
Long Term Debt	237.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7M	13.5M	17.3M
Other Non-Current Liabilities	-14.3M	0.0	0.0	0.0	0.0	0.0	0.0	748K	906K	908K	665K
Total Non-Current Liabilities	237.3M	15.9M	17.5M	18.2M	831K	3.2M	4.4M	748K	9.6M	14.4M	18M
Capital Lease Obligations	14.4M	17.5M	18.9M	19.6M	3.2M	5.2M	6M	0.0	0.0	0.0	0.0
Total Liabilities	301.2M	71.6M	55.6M	45.1M	17.9M	16.2M	17.7M	25.7M	20.8M	23.2M	25.3M
SHAREHOLDERS' EQUITY
Preferred Stock	89.4M	110.6M	60M	65.8M	85.4M	110.9M	0.0	85.9M	77.2M	77.1M	77M
Common Stock	161K	110K	86K	70K	44K	32K	8K	30K	10K	10K	16K
Additional Paid-In Capital	1.7B	1B	801.1M	601.2M	399.7M	322.5M	155.6M	152.3M	2.5M	1.2M	0.0
Retained Earnings	-1.2B	-859.5M	-603.6M	-411.2M	-271M	-198.7M	-123.9M	-92.1M	-51.3M	-25.8M	-7.7M
Accumulated Other Comprehensive Income/Loss	355K	447K	246K	-104K	0.0	0.0	0.0	-12K	-16K	-24K	-16K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	221K
Total Stockholders' Equity	636.4M	256.3M	257.8M	255.7M	214.2M	234.7M	31.8M	60.2M	28.3M	52.4M	69.5M
Total Equity	636.4M	256.3M	257.8M	255.7M	214.2M	234.7M	31.8M	60.2M	28.3M	52.4M	69.5M
SUMMARY
Total Liabilities & Equity	937.6M	327.9M	313.4M	300.8M	232.1M	250.9M	49.4M	85.9M	49.1M	75.6M	94.8M
Total Investments	588.8M	188.9M	219.9M	119.4M	0.0	0.0	0.0	22.9M	13.9M	28.4M	1.3M
Total Debt	253.2M	17.5M	18.9M	19.6M	3.2M	5.2M	6M	0.0	0.0	0.0	0.0
Net Debt	-58.9M	-80.7M	-34.4M	-120.2M	-216.5M	-237M	-31.4M	-55.7M	-28.3M	-41.3M	-90.5M
Shares Outstanding	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618	142,452,618

SEC Filings

COGT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 09, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 18, 2025	November 18, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 11, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 07, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 145 filings

Related Guides

Blog Categories

Continue your COGT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.